Adaptive Biotechnologies Corpor (ADPT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $14.18, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Illumina; Negative momentum.
Adaptive Biotechnologies develops clonoSEQ, the FDA-authorized MRD diagnostic test for lymphoid cancers, plus an IM business licensing immune receptor data to biopharma partners. Total revenue was $277M in 2025, driven by 105,587 clonoSEQ tests (46% growth) and 180+ active... Read more
Hold if already holding. Not a fresh buy at $14.18, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Illumina; Negative momentum. Chart setup: Death cross but MACD improving, RSI 50. Mixed signals. Hold existing position. Score 5.8/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierIllumina10-K Item 1A: 'Illumina supplies us with reagents that have been designed for use solely with these sequencers and Illumina is the sole provider of maintenance and repair services for the Illumina NextSeq System and the NovaSeq X Plus System.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $14.18, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Illumina; Negative momentum. Chart setup: Death cross but MACD improving, RSI 50. Mixed signals. Hold existing position. Target $17.90 (+26.2%), stop $13.11 (−8.2%), A.R:R 2.2:1. Score 5.8/10, moderate confidence.
Take-profit target: $17.90 (+27.0% upside). Target $17.90 (+26.2%), stop $13.11 (−8.2%), A.R:R 2.2:1. Stop-loss: $13.11.
Concentration risk — Supplier: Illumina; Negative momentum; Elevated risk factors.
Adaptive Biotechnologies Corpor trades at a P/E of N/A (forward -52.5). TrendMatrix value score: 7.3/10. Verdict: Hold.
14 analysts cover ADPT with a consensus score of 4.2/5. Average price target: $21.
What does Adaptive Biotechnologies Corpor do?Adaptive Biotechnologies develops clonoSEQ, the FDA-authorized MRD diagnostic test for lymphoid cancers, plus an IM...
Adaptive Biotechnologies develops clonoSEQ, the FDA-authorized MRD diagnostic test for lymphoid cancers, plus an IM business licensing immune receptor data to biopharma partners. Total revenue was $277M in 2025, driven by 105,587 clonoSEQ tests (46% growth) and 180+ active biopharma trials. Illumina is the sole provider of sequencers, reagents, and maintenance services for its lab operations.